Skip to main content
. 2019 Aug 7;8(9):654–663. doi: 10.1002/psp4.12446

Figure 2.

Figure 2

Pharmacokinetic (PK) parameters at steady state following intravenous (i.v.) administration vs. age in the phase III clinical study based on the population PK model for AUC (0–24 h) and C max . Open circles indicate subjects with multiple‐dose i.v. administration of 400 mg once daily; filled circles, subjects with multiple‐dose i.v. administration of 4–6 mg/kg twice daily; asterisks, subjects with any treatment and with at least one noninfluential outlier; dashed lines, limits of the C max target range. AUC (0–24 h) , 24‐hour area under the concentration‐time curve; C max , maximum plasma concentration.